Study S000552

A Randomized, Double-blind, Placebo and Active Comparator-controlled Phase 2 Study to Evaluate the Efficacy and Safety of HDM1005 in Subjects With T2DM With Inadequate Glycemic Control After Diet/Exercise or Metformin Therapy

ClinicalTrials.gov record

Registration

Registration: NCT07109700
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 216
Start: 2025-04-30
Primary completion: 2026-01-31
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:HDM1005 3; DRUG:HDM1005 4; DRUG:Placebo; DRUG:Dulaglutide 1.5 MG
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 20]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.